Sunday Dec 1
The Indianapolis Star
One drug, many uses. Good idea?
So did you get enough to eat this past week? Did you find it hard to choose between seconds on the... For Lilly, Cymbalta means new revenue without a new pill.
The Raw Story
Slate's 'minutes to read' feature dumbs down journalism
This article will take you 3 minutes 45 seconds to read. You will expend 60 calories and learn two new vocabulary words, including a synonym for "rebellious".
It's Time To Buy Tonix Pharmaceuticals
Tonix Pharmaceuticals is developing TNX-102SL, a sublingual formulation of cyclobenzaprine for the treatment of fibromyalgia syndrome.
Eli Lilly Goes Down The Hill As Patents Expire
Loss of exclusivity whether by expiration or as a consequence of litigation typically results in a rapid and severe decline in sales for drug manufacturers like Eli Lilly and Company .
Disease-Focused Businesses Prepare For Impact Of Healthcare Reform As 2014 Nears
Decision Resources Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that market access is drastically changing for companies focused on a wide range of specific indications, including schizophrenia, diabetes and prostate cancer.
Report: Generics Will Constrain Growth of Neuropathic Pain Drug Market
Decision Resources, a research and advisory firm located in Burlingon, Mass., finds that the loss of U.S. and European market exclusivity of three sales-leading drugs for neuropathic pain - delayed-release duloxetine , lidocaine dermal patch , and pregabalin - combined with a lack of transformative emerging therapies forecasted to launch ... (more)